[
  {
    "ts": "2026-01-10T08:12:10+00:00",
    "headline": "Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed",
    "summary": "Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P. Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal’s MASH franchise. We’ll now examine how Wolfe Research’s valuation downgrade, alongside...",
    "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-mdgl-down-13-081210592.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5c6b4c6d-6f6b-3d56-b934-ebbb50f116a6",
      "content": {
        "id": "5c6b4c6d-6f6b-3d56-b934-ebbb50f116a6",
        "contentType": "STORY",
        "title": "Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed",
        "description": "",
        "summary": "Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P. Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal’s MASH franchise. We’ll now examine how Wolfe Research’s valuation downgrade, alongside...",
        "pubDate": "2026-01-10T08:12:10Z",
        "displayTime": "2026-01-10T08:12:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-mdgl-down-13-081210592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-mdgl-down-13-081210592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]